BETd-260
This product is a small-molecule PROTAC degrader that targets BET family proteins. It recruits cereblon (CRBN) E3 ligase, specifically enabling targeted ubiquitination and proteasomal degradation of BRD2, BRD3, and BRD4.
Key Features and Benefits
-
BET Degrader: Selectively degrades BRD2, BRD3, and BRD4 proteins.
-
CRBN Recruitment: Utilizes cereblon E3 ligase for targeted degradation.
-
PROTAC Design: Combines a BET ligand with an E3-binding ligand.
-
High Specificity: Reduces off-target effects compared to traditional inhibitors.
-
High Purity: Ensures reproducibility in chemical biology and drug discovery workflows.
Applications
-
Targeted Protein Degradation: Investigates the role of BET proteins in biology and disease.
-
Cancer Research: Studies BET dependency in hematologic and solid tumors.
-
Epigenetics: Explores regulation of gene transcription by BET protein removal.
-
Drug Discovery: Serves as a chemical probe for PROTAC development.
Storage and Handling
-
Storage: Store at –20 °C in a sealed, light- and moisture-protected container.
-
Handling: Use anhydrous solvents such as DMSO; avoid prolonged exposure to moisture and heat.
This product integrates BET protein targeting with CRBN recruitment, specifically providing a potent PROTAC degrader for epigenetic and cancer research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.